
BiotechTV - News BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
Jun 17, 2025
Chapters
Transcript
Episode notes

BiotechTV - News